The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Open accessAbstract
Cancer incidence is rising and this global challenge is further exacerbated by tumour resistance to available medicines. A promising approach to meet the need for improved cancer treatment is drug repurposing. Here we highlight the potential for repurposing disulfiram (also known by the trade name Antabuse), an old alcohol-aversion drug that has been shown to be effective against diverse cancer types in preclinical studies. Our nationwide epidemiological study reveals that patients who continuously used disulfiram have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis. Moreover, we identify the ditiocarb-copper complex as the metabolite of disulfiram that is responsible for its anti-cancer effects, and provide methods to detect preferential accumulation of the complex in tumours and candidate biomarkers to analyse its effect on cells and tissues. Finally, our functional and biophysical analyses reveal the molecular target of disulfiram's tumour-suppressing effects as NPL4, an adaptor of p97 (also known as VCP) segregase, which is essential for the turnover of proteins involved in multiple regulatory and stress-response pathways in cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DIS`s definitive antineoplastic mechanism of action, identified over the past decade, involves the molecular target NPL4, which is an adapter for the p97/VCP segregase and is essential for protein turnover, playing a role in several regulatory and stress-responsive cellular pathways.26”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a nationwide epidemiological study revealed that patients who continuously used DIS have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis.26”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“This triggers a multifaceted cellular stress response culminating in cell death,26”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Intracellular Cu(DDC)2 binds NPL4, inducing aggregation that disrupts the essential p97-NPL4-UFD1 segregase pathway.”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“DIS’s cytotoxic activity stems from its rapid metabolism to Cu(DDC)2, which preferentially accumulates in tumors.”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“This initial observation has since been substantiated through extensive research, including analyses of Danish demographic and health registries that observed lower mortality rates for colon, prostate, and breast cancers among ongoing DSF users compared to former users.111”
From Drug repurposing for cancer therapy (2024) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Molecular Chaperone Functions in Protein Folding and Proteostasis
Kim, Y., Hipp, M. S., Bracher, A., Hayer-Hartl, M. K., & Hartl, F. U. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060208-092442 · Cited by 1,545
Target identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gómez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,130
Thygesen, L. C., Daasnes, C., Thaulow, I., & Brønnum‐Hansen, H. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811399956 · Cited by 1,089
Role of Rpn11 Metalloprotease in Deubiquitination and Degradation by the 26 S Proteasome
Verma, R., Aravind, L., Oania, R. S., McDonald, W. H., Yates, J. R., Koonin, E. V., & Deshaies, R. J. (2002) · Science · doi:10.1126/science.1075898 · Cited by 994
Self-citationDoil, C., Mailand, N., Bekker‐Jensen, S., Ménard, P., Larsen, D. H., Pepperkok, R., Ellenberg, J., Panier, S., Durocher, D., Bártek, J., et al. (2009) · Cell · doi:10.1016/j.cell.2008.12.041 · Cited by 982
Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system
Meyer, H. H., Bug, M., & Bremer, S. (2012) · Nature Cell Biology · doi:10.1038/ncb2407 · Cited by 832
Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2126 · Cited by 683
Self-citationCell death assays for drug discovery
Kepp, O., Galluzzi, L., Lipinski, M. M., Yuan, J., & Kroemer, G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3373 · Cited by 587
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., et al. (2017) · Nature · doi:10.1038/nature22038 · Cited by 571
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 812
Co-delivery Systems of Multiple Drugs Using Nanotechnology for Future Cancer Therapy
Fumoto, S., & Nishida, K. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00008 · Cited by 43
Sun, Y., An, C., Wu, L., Zeng, W., Wang, J., Wang, Y., He, J., Gao, G., & Ye, D. (2021) · ACS Nano · doi:10.1021/acsnano.1c05485 · Cited by 44
Zheng, X., Liu, Z., Mi, M., Wen, Q., Wu, G., & Zhang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734853 · Cited by 44
Wang, R., Song, W., Zhu, J., Shao, X., Yang, C., Xiong, W., Wang, B., Zhao, P., Chen, M., & Huang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.004 · Cited by 43
Zeng, C., Nie, D., Wang, X., Zhong, S., Zeng, X., Liu, X., Qiu, K., Peng, X., Zhang, W., Chen, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02162-0 · Cited by 42
Anwer, M. S., Abdel-Rasol, M. A., & El-Sayed, W. M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01631-0 · Cited by 45
Falls-Hubert, K. C., Butler, A. L., Gui, K., Anderson, M., Li, M., Stolwijk, J. M., Rodman, S. N., Solst, S. R., Tomanek‐Chalkley, A., Searby, C. C., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.01.186 · Cited by 42
Narkhede, H. I., Dhake, A. S., & Surana, A. R. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105832 · Cited by 42
Li, J., Lv, X., Li, J., Jin, W., Chen, Z., Wen, Y., Pei, Z., & Pei, Y. (2023) · Organic Chemistry Frontiers · doi:10.1039/d3qo00065f · Cited by 41
Self-citationHu, H., Zhang, W., Lei, L., Tong, F., Zhang, H., Zhang, Y., Yang, W., Tang, Y., Lin, R., Xia, X., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108765 · Cited by 41
Self-citationROS-generating nanoplatforms as selective and tunable therapeutic weapons against cancer
Foglietta, F., Serpe, L., & Canaparo, R. (2023) · Discover Nano · doi:10.1186/s11671-023-03939-w · Cited by 41
An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment
Yang, Q., Yao, Y., Li, K., Jiao, L., Zhu, J., Ni, C., Li, M., Dou, Q. P., & Yang, H. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190816233755 · Cited by 41
Self-citationZhang, H., Song, F., Dong, C., Yu, L., Chang, C., & Chen, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01025-w · Cited by 42
Copper-Based Nanomedicines for Cuproptosis-Mediated Effective Cancer Treatment
Noh, D., Lee, H., Lee, S., Sun, I., & Yoon, H. Y. (2024) · Biomaterials Research · doi:10.34133/bmr.0094 · Cited by 41
Tackling cuproptosis: from metabolic rewiring to therapeutic exploitation in cancer
Hao, Q., Gan, Y., & Zhou, X. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01387-x · Cited by 43
Label-free target identification in drug discovery via phenotypic screening
Park, H., Ha, J., & Park, S. B. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.006 · Cited by 40
Ren, L., Feng, W., Shao, J., Ma, J., Xu, M., Zhu, B., Zheng, N., & Liu, S. (2020) · Theranostics · doi:10.7150/thno.45558 · Cited by 40
Li, C., Zhou, S., Chen, C., Zhu, L., Li, S., Song, Z., Liang, J., Tang, C., Xu, N., Liu, T., et al. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113253 · Cited by 40
Chen, Y., Sun, J., Liu, J., Wei, Y., Wang, X., Fang, H., Du, H., Huang, J., Li, Q., Ren, G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007487 · Cited by 40
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Gao, X., Zhao, H., Liu, J., Wang, M., Dai, Z., Hao, W., Wang, Y., Wang, X., Zhang, M., Liu, P., et al. (2024) · Advanced Science · doi:10.1002/advs.202401396 · Cited by 39
Metal-based immunogenic cell death inducers for cancer immunotherapy
Zou, J. X., Chang, M. R., Kuznetsov, N. A., Kee, J. X., Babak, M. V., & Ang, W. H. (2025) · Chemical Science · doi:10.1039/d4sc08495k · Cited by 42
Advanced biomimetic nanoreactor for specifically killing tumor cells through multi-enzyme cascade
Liu, W., Wu, J., Ji, X., Ma, Y., Liu, L., Zong, X., Yang, H., Dai, J., Chen, X. S., & Xue, W. (2020) · Theranostics · doi:10.7150/thno.45456 · Cited by 39
Wang, K., Michelakos, T. P., Wang, B., Shang, Z., DeLeo, A. B., Duan, Z., Hornicek, F. J., Schwab, J. H., & Wang, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.002 · Cited by 39
Tang, Y., Fan, Y., Wang, Y., Wang, D., Huang, Q., Chen, T., Cao, X., Wen, C., Shen, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116658 · Cited by 38
Self-citationZuhra, K., Panagaki, T., Randi, E. B., Augsburger, F., Blondel, M., Friocourt, G., Hérault, Y., & Szabó, C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114267 · Cited by 38
Emerging Cancer Therapeutic Targets in Protein Homeostasis
Bastola, P., Oien, D. B., Cooley, M., & CHIEN, J. R. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0254-1 · Cited by 39
Application of Disulfiram and its Metabolites in Treatment of Inflammatory Disorders
Guo, W., Chen, S., Li, C., Xu, J., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.795078 · Cited by 38
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
Buchtová, T., Lukáč, D., Škrott, Z., Chromá, K., Bártek, J., & Mistrík, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032885 · Cited by 38
GAN, Y., Liu, T., Feng, W., Wang, L., LI, L., & Ning, Y. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028694 · Cited by 38
Zhang, H., Yang, L., Han, M., Han, Y., Jiang, Z., Zheng, Q., Dong, J., Wang, T., & Li, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c04553 · Cited by 38
Defect Engineering of Mesoporous Silica Nanoparticles for Biomedical Applications
Yang, B., & Shi, J. (2021) · Accounts of Materials Research · doi:10.1021/accountsmr.1c00055 · Cited by 38
Cuproptosis: emerging biomarkers and potential therapeutics in cancers
Wang, M., Zheng, L., Ma, S., Lin, R., Li, J., & Yang, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288504 · Cited by 38
Self-citationXiao, C., Li, J., Hua, A., Wang, X., Li, S., Li, Z., Chen, X., Zhang, Z., Yang, X., & Li, Z. (2024) · Research · doi:10.34133/research.0335 · Cited by 36
Self-citationYang, S., Li, X., Yan, J., Jiang, F., Fan, X., Jin, J., Zhang, W., Zhong, D., & Li, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-64981-x · Cited by 36
Tan, W. W., Jänsch, N., Öhlmann, T., Meyer‐Almes, F., & Jiang, X. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02784 · Cited by 36
Gao, Z., Li, Y., Zhang, Y., An, P., Chen, F., Chen, J., You, C., Wang, Z., & Sun, B. (2020) · Nanoscale · doi:10.1039/d0nr00434k · Cited by 36
Du, C., Guan, X., Liu, Y., Xu, Z., Du, X., Li, B., Wang, M., & Zheng, Z. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04398-3 · Cited by 36
Metformin reveals a mitochondrial copper addiction of mesenchymal cancer cells
Müller, S., Versini, A., Sindikubwabo, F., Belthier, G., Niyomchon, S., Pannequin, J., Grimaud, L., Cañeque, T., & Rodriguez, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206764 · Cited by 35
Lü, X., Liu, Y.-C., Orvig, C., Liang, H., & Chen, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111567 · Cited by 35
Gao, C., Guo, W., Guo, X., Ding, Z., Ding, Y., & Shen, X. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.041 · Cited by 35
Drug repositioning: A bibliometric analysis
Sun, G., Dong, D., Dong, Z., Zhang, Q., Fang, H., Wang, C., Zhang, S., Wu, S., Dong, Y., & Wan, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.974849 · Cited by 36
Solovieva, M. E., Shatalin, Y. V., Solovyev, V. V., Sazonov, A. V., Kutyshenko, V. P., & Акатов, В. С. (2018) · Redox Biology · doi:10.1016/j.redox.2018.09.016 · Cited by 34
Buffet-style Cu(II) for enhance disulfiram-based cancer therapy
Zhao, L., Wang, X., Lou, H., Jiang, M., Wu, X., Qin, J., Zhang, J., Guan, X., Li, W., Zhang, W., et al. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.06.009 · Cited by 34
Huang, J., Campian, J. L., DeWees, T. A., Skrott, Z., Mistrik, M., Johanns, T. M., Ansstas, G., Butt, O., Leuthardt, E., Dunn, G. P., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.05.009 · Cited by 34
Zhou, L., Liu, Y., Yang, C., Liu, Y., Chen, Q., Pan, W., Cai, Q., Luo, L., Liu, L., Jiang, S., et al. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2414-5 · Cited by 34
Proteasome inhibition in multiple myeloma: lessons for other cancers
Saavedra-García, P., Martini, F., & Auner, H. W. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00286.2019 · Cited by 34
Kang, X., Cai, Y., Wang, Q., Wang, C., Chen, W., Yang, W. L., Suryawanshi, A. S., Zhou, G., Chen, P., & Li, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120972 · Cited by 34
Chen, C., Nie, D., Huang, Y., Yu, X., Chen, Z., Zhong, M., Liu, X., Wang, X., Sui, S., Liu, Z., et al. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ma1121-644r · Cited by 34
Chen, Y., Sheng, D., Wang, F., Rao, W., Shen, S., & Wang, S. (2022) · Organic Chemistry Frontiers · doi:10.1039/d2qo00945e · Cited by 34
Huang, Z., Ding, Y., Luo, Y., Chen, M., Zeng, Z., Zhang, T., Sun, Y., Huang, Y., & Zhao, C. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.072 · Cited by 34
Huang, Y., Xu, Y., Song, R., Ni, S., Liu, J., Xu, Y., Ren, Y., Rao, L., Wang, Y., Wei, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00699 · Cited by 33
Self-citationXanthis, V., Mantso, T., Dimtsi, A., Pappa, A., & Fadouloglou, V. E. (2023) · Cancers · doi:10.3390/cancers15174419 · Cited by 35
Jakola, A. S., Werlenius, K., Mudaisi, M., Hylin, S., Kinhult, S., Bartek, J., Salvesen, Ø. O., Carlsen, S. M., Strandéus, M., Lindskog, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.16786.1 · Cited by 34
Self-citationMajera, D., Škrott, Z., Bouchal, J., Bártková, J., Šimková, D., Gachechiladze, M. A., Steigerová, J., Kurfürstová, D., Gurský, J., Kořínková, G., et al. (2018) · The Prostate · doi:10.1002/pros.23741 · Cited by 33
Self-citationRieber, M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200628022113 · Cited by 33
Activation of autophagy by in situ Zn2+ chelation reaction for enhanced tumor chemoimmunotherapy
Yang, Y., Zhu, Y., Wang, K., Miao, Y., Zhang, Y., Gao, J., Qin, H., & Zhang, Y. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.06.022 · Cited by 33
Goto, K., Arai, J., Stephanou, A., & Kato, N. (2018) · Oncotarget · doi:10.18632/oncotarget.24568 · Cited by 33
Sensitizing cuproptosis by endogenous copper-triggered bioorthogonal nanoremodeler
Zhu, J., You, Y., Zhang, B., Wang, W., Jiang, M., Pu, F., Ren, J., & Qu, X. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102196 · Cited by 32
Zhang, Z., Zhao, Q., Xu, Q., Deng, Q., Hua, A., Wang, X., Yang, X., & Li, Z. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123094 · Cited by 32
Chen, X., Yang, Q., Chen, J., Zhang, P., Huang, Q., Zhang, X., Li, Y., Xu, D., Zhao, C., Wang, X., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493041 · Cited by 32
MiRNA Polymorphisms and Cancer Prognosis: A Systematic Review and Meta-Analysis
Ding, H.-X., Lv, Z., Yuan, Y., & Xu, Q. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00596 · Cited by 32
Chang, Y., Wu, F., Pandey, N. K., Chudal, L., Xing, M., Zhang, X., Nguyen, L., Liu, X., Liu, J. P., Chen, W., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00949 · Cited by 32
Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics
Rai, A., Noor, S., Ahmad, S. I., Alajmi, M. F., Hussain, A., Abbas, H., & Hasan, G. M. (2021) · Medicina · doi:10.3390/medicina57020091 · Cited by 32
Yarza, R., Bover, M., Agulló-Ortuño, M. T., & Docampo, L. C. I. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02010-9 · Cited by 33
Zhao, P., Qu, J., Wu, A., Wang, S., Tang, X., Ou, A., Zhang, J., Xu, Y., Zhao, Q., & Huang, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101448 · Cited by 32
Zhang, Q., Chen, Z., Tang, Q., Wang, Z., Lu, J., You, Y., & Wang, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05163-3 · Cited by 32
Kang, X., Wang, J., Huang, C.-H., Wibowo, F. S., Amin, R., Chen, P., & Li, F. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102620 · Cited by 32
Almotairy, A., Alyahya, M., Althobaiti, A. A., Almutairi, M., Bandari, S., Ashour, E. A., & Repka, M. A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122709 · Cited by 32
Hydroxyethyl starch stabilized copper-diethyldithiocarbamate nanocrystals for cancer therapy
Xiao, C., Li, J., Wang, X., Li, S., Xu, C., Zhang, Z., Hua, A., Ding, Z., Zhang, B., Yang, X., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.043 · Cited by 33
Self-citationChen, C., Cai, J., Shi, J., Wang, Z., & Liu, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-05173-7 · Cited by 31
Yang, L., Yao, C., Su, Z., Fang, Y., Pandey, N. K., Amador, E. H., Diao, T., Guo, B. K., Cao, D., Chen, X., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.02.009 · Cited by 31
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
Esposito, M., Amory, J. K., & Kang, Y. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240519 · Cited by 32
Liu, T., Wang, P., Cong, M., Zhao, X., Zhang, D., Xu, H., Liu, L., Jia, J., & You, H. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14503 · Cited by 31
Yoshino, H., Yamada, Y., Enokida, H., Osako, Y., Tsuruda, M., Kuroshima, K., Sakaguchi, T., Sugita, S., Tatarano, S., & Nakagawa, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236119 · Cited by 30
Zhang, H., Zhang, Q., Guo, Z., Liang, K., Boyer, C. A., Liu, J., Zheng, Z., Amal, R., Yun, S. L. J., & Gu, Z. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.01.187 · Cited by 30
Zhang, H., Wang, T., Liu, H., Han, Y., Zheng, Q. Y., Xu, Q., Bao, B., Xing, W., & Li, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101601 · Cited by 30
Li, X., Du, K., Sun, J., & Feng, F. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01014 · Cited by 30
A Class of Disulfide Compounds Suppresses Ferroptosis by Stabilizing GPX4
Liu, J.-P., Cen, S.-Y., Xue, Z., Wang, T.-X., Gao, Y., Zheng, J., Zhang, C., Hu, J., Nie, S., Xiong, Y., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00445 · Cited by 29
Xie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
Higgins, R. K., Kabbaj, M.-H. M., Sherwin, D., Howell, L. A., Hatcher, A., Tomko, R. J., & Wang, Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107898 · Cited by 29
Combining repurposed drugs to treat colorectal cancer
Duarte, D., & Vale, N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.012 · Cited by 29
Structural basis of ubiquitin‐independent PP1 complex disassembly by p97
van den Boom, J., Marini, G., Meyer, H. H., & Saibil, H. R. (2023) · The EMBO Journal · doi:10.15252/embj.2022113110 · Cited by 29
Zhong, J., Zheng, X., Wen, Y., Wang, S., Zhan, G., & Chen, A. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145795 · Cited by 28
Cuproptosis Nanomedicine: Clinical challenges and opportunities for anti-tumor therapy
Liu, Y., Chen, G., You, X., & Wang, X. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.153373 · Cited by 28
Wang, Y., Zhou, Q., Luo, W., Yang, X., Zhang, J., Lou, Y., Jin, M., Chen, J., Wu, F., Hou, J., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02968-6 · Cited by 30
The Scripps Molecular Screening Center and Translational Research Institute
Baillargeon, P., Fernández-Vega, V., Sridharan, B. P., Brown, S. J., Griffin, P. R., Rosen, H., Cravatt, B. F., Scampavia, L. D., & Spicer, T. (2019) · SLAS DISCOVERY · doi:10.1177/2472555218820809 · Cited by 28
Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells
Gao, L., Huang, S., Zhang, H., Hua, W., Xin, S., Cheng, L., Guan, W., Yu, Y., Mao, Y. Q., & Pei, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-39852-5 · Cited by 28
COP9 signalosome is an essential and druggable parasite target that regulates protein degradation
Ghosh, S., Farr, L. A., Singh, A., Leaton, L. A., Padalia, J., Shirley, D.-A. T., Sullivan, D. J., & Moonah, S. N. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008952 · Cited by 28
Copper(II)-disulfiram loaded melanin-dots for cancer theranostics
Shi, H., Suo, Y., Zhang, Z., Liu, R., Liu, H., & Cheng, Z. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102340 · Cited by 28
Peng, X., Pan, Q., Li, J., Zhu, W., Zhang, N., Pu, Y., Luo, K., & He, B. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2020.100931 · Cited by 28
Self-citationShen, J., Zhou, W., Jia, M., Yang, X., Lin, J., An, L., Tian, Q., & Yang, S. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00521 · Cited by 28
Urano, F., Kitamura, R. A., Maxwell, K. G., Ye, W., Kries, K., BROWN, C. M., Augsornworawat, P., Johansson, M., Cohen, J. N., Klee, J. B., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.01.299 · Cited by 33
Kanellis, D. C., Zisi, A., Skrott, Z., Lemmens, B., Espinoza, J. A., Kosar, M., Björkman, A., Li, X., Arampatzis, S., Bartkova, J., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01167-4 · Cited by 27
Tao, X., Wang, H., Wang, Q., Wang, C., Shao, C.-W., Jin, Y., Yu, D., Hu, H., Zhang, Q., Xu, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07917 · Cited by 27
Zhao, Y., Lin, M.-T., Lan, Q.-H., Zhai, Y., Xu, H., Xiao, J., Kou, L., & Yao, Q. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00604 · Cited by 27
Yang, L., Yang, J., Liu, H., Lan, J., Xu, Y., Wu, X., Mao, Y., Wu, D., Pan, K., & Zhang, T. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70708 · Cited by 27
Regulation of anti-tumor immunity by metal ion in the tumor microenvironment
Gao, Y., Liu, S., Huang, Y., Li, F., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379365 · Cited by 26
Biswas, M., Choudhury, K. K., Banerjee, A., & Pathak, R. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216026 · Cited by 26
Jia, J., Lin, R., Liu, M., Hou, M., Yu, H., Lu, Q., Ma, Y., Zhao, T., Zhang, F., Mady, M. F., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14011 · Cited by 26
Yang, W., Xiao, C., Zheng, J., Song, J., & Li, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107988 · Cited by 27
Metadata
- Authors
- Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., Kraus, M., Michalova, M., Vaclavkova, J., Dzubak, P., Vrobel, I., Pouckova, P., Sedlacek, J., Miklovicova, A., Kutt, A., Li, J., Mattova, J., Driessen, C., Dou, Q. P., Olsen, J., Hajduch, M., Cvek, B., Deshaies, R. J., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- Institute of Molecular and Translational Medicine (CZ)
- Kantonsspital St. Gallen (CH)
- Charles University (CZ)
- Nemocnice Šternberk (CZ)
- California Institute of Technology (US)
- Wayne State University (US)
- Palacký University Olomouc (CZ)
- Corresponding author
- Cvek, Boris
- Deshaies, Raymond J.
- ORCID
- Venue
- Nature
- Published
- 2017-12
- Volume
- 552
- Issue
- 7684
- Pages
- 194-199
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5730499
- OpenAlex
- W2772508026
- Cited by
- 807
- References
- 53
- Citations by year
- 2026: 76 · 2025: 108 · 2024: 120 · 2023: 108 · 2022: 112 · 2021: 81 · 2020: 92 · 2019: 60 · 2018: 50
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Lundbeckfonden (R93-2011-8990)
- National Cancer Institute (R01CA164803)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- disulfiram, drug repurposing, cancer, Npl4, VCP, diethyldithiocarbamate, cancer mortality, tumor suppression, protein turnover, stress response, biomarkers, cell death
- MeSH terms
- Adult, Alcohol Deterrents, Alcoholism, Animals, Antineoplastic Agents, Copper, Denmark, Disulfiram, Female, Humans, Male, Middle Aged, Neoplasms, Nuclear Proteins, Protein Binding, Heat-Shock Response, Mice, Drug Repositioning, Molecular Targeted Therapy, Proteolysis, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
